The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Macrophage reprogramming and response to PD-1 blockade in smoldering myeloma
Irene Ghobrial, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the role of macrophage reprogramming in determining responses to PD-1 blockade in high-risk smoldering multiple myeloma. Dr Ghobrial highlights findings from a study of nivolumab plus lenalidomide, exploring differences in immune responses and the importance of understanding interactions between T cells, macrophages, and the tumor microenvironment through spatial proteomics and transcriptomics. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
